文献速递乳腺癌放疗

接受大分割放射治疗的乳腺癌患者报告的晚期毒性症状及其与生活质量的关系

Patient-Reported Symptoms of Late Toxicity in Patients With Breast Cancer Treated With Hypofractionated Radiation Therapy and the Association With Quality of Life.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-11-17

在Utrecht乳腺癌干预研究和长期评估前瞻性队列中,向放疗后≥12个月的乳腺癌患者发放自报晚期毒性问卷,评估大分割放疗(40 Gy/15次或42.5 Gy/16次,伴或不伴同步整合加量)后患者报告的晚期毒性症状及其与生活质量的关系。16%(265/1613)患者报告晚期毒性,中位放疗至问卷间隔38个月,晚期毒性患者接受镇痛药、物理治疗和淋巴水肿治疗的比例显著更高。

要点

  • 16%(265例)患者报告晚期毒性,中位放疗至问卷间隔38个月(四分位距21-55)。
  • 中度/重度乳房变硬、胸壁疼痛和乳房疼痛分别占18%(295例)、14%(225例)和10%(140例)。
  • 晚期毒性患者中13%至52%存在临床相关功能损害,无晚期毒性患者中为2%至26%。

核心结论

  • 本研究揭示了大分割放疗后患者报告的晚期毒性患病率及其对乳腺癌后生活质量的影响,结果可能有助于医疗专业人员向患者告知乳腺癌治疗(包括大分割放疗)的长期影响。

研究设计与样本

  • 前瞻性Utrecht乳腺癌干预研究和长期评估队列中,向放疗后≥12个月、以治愈为目的治疗的乳腺癌患者发放自报晚期毒性问卷。
  • 患者接受大分割放疗40 Gy/15次或42.5 Gy/16次,伴或不伴同步整合加量;晚期毒性症状采用4点Likert量表评估。

主要发现

  • 1613/2248例患者(72%)纳入研究,其中16%(265例)报告晚期毒性。
  • 中度/重度乳房变硬、胸壁疼痛和乳房疼痛分别占18%(295例)、14%(225例)和10%(140例)。
  • 晚期毒性患者中13%至52%存在临床相关功能损害(躯体、角色和社会功能低于临床阈值),无晚期毒性患者中为2%至26%。
  • 晚期毒性患者较无晚期毒性患者显著更常接受镇痛药、物理治疗和淋巴水肿治疗。

关键数值与推荐

  • 晚期毒性定义为中度至重度乳房或胸壁疼痛合并至少1种其他轻至重度晚期毒性症状,即乳房或手臂/手淋巴水肿、乳房变硬或手臂活动受限。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to assess the prevalence of patient-reported symptoms of local late toxicity in patients with irradiated breast cancer and determine the association between late toxicity and quality of life. METHODS: Within the prospective Utrecht cohort for Multiple BReast cancer intErvention studies and Long-term evaluation cohort, a survey on self-reported late toxicity was sent to all patients with breast cancer with ≥12 months interval since radiation therapy treated with curative intent. Patients were treated with hypofractionated radiation therapy of 40 Gy/15 fractions or 42.5 Gy/16 fractions, with or without a simultaneous integrated boost. Symptoms of late toxicity were evaluated on a 4-point Likert scale. Late toxicity was defined as moderate-severe breast or chest wall pain combined with at least 1 other mild-severe late toxicity symptom, that is, breast or arm/hand lymphedema, firmness of the breast, or impaired arm movement. Physical, role, and social functioning were measured before, during, and after the late toxicity survey using the European Organization for Research and Treatment of Cancer Quality of Life Core questionnaire-C30 and compared with a Dutch normative population. RESULTS: In the study, 1613/2248 patients (72%) were included. Of those, 16% (n = 265) reported late toxicity. The median time interval between radiation therapy and survey was 38 months (interquartile range, 21-55). Moderate/severe firmness of the breast, chest wall pain, and breast pain were reported by, respectively, 18% (n = 295), 14% (n = 225), and 10% (n = 140) of all patients. Physical, role, and social functioning were below the clinical threshold (ie, clinically relevant impairment) in 13% to 52% of patients with late toxicity and 2% to 26% of patients without late toxicity. Patients with late toxicity significantly more often received analgesics, physiotherapy, and lymphedema therapy compared with patients without late toxicity. CONCLUSIONS: This study provided insight into the prevalence of patient-reported late toxicity after hypofractionated radiation therapy and the influence of late toxicity on quality of life after breast cancer. These results may help health care professionals to inform their patients about long-term effects of breast cancer treatment including hypofractionated radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Batenburg MCT, Mink van der Molen DR, van der Leij F, et al. Patient-Reported Symptoms of Late Toxicity in Patients With Breast Cancer Treated With Hypofractionated Radiation Therapy and the Association With Quality of Life. Int J Radiat Oncol Biol Phys. 2022. PMID: 36402357. doi:10.1016/j.ijrobp.2022.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。